Opinion|Videos|January 13, 2025
Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
Author(s)Amrita Krishnan, MD
Amrita Krishnan, MD, discusses how an ASH 2024 abstract from Sylvester Comprehensive Cancer Center suggests the potential of tocilizumab prophylaxis to mitigate cytokine release syndrome (CRS) in patients treated with bispecific therapies for multiple myeloma, and shares her approach to managing unique toxicities such as nail changes, skin reactions, and oral complications in patients receiving talquetamab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- An ASH abstract from the group at Sylvester Comprehensive Cancer Center highlighted the potential of using tocilizumab prophylactically to mitigate CRS in patients treated with bispecific therapies for multiple myeloma. What are your thoughts on this approach, and how might it change current CRS prevention protocols?
- Talquetamab has unique toxicities such as nail changes, skin reactions, and oral complications. What are your recommendations for effectively managing these adverse events?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust
3
New Dermatologic Therapies Make Waves at Maui Derm 2026
4
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
5
